Science, research and development European Commission
Dr Fergal DONNELLYBiotechnology and Applied Genomics Unit
Research Directorate GeneralEuropean Commission
Application of knowledge and technologies in the field of genomics and biotechnology for health
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Warsaw, POLAND, 22 6.2004
Science, research and development European Commission
(Source: EFPIA)
• Employment : about 560,000 jobs in Europe, including 88,200 in R&D units
The pharmaceutical industry remains one of Europe’s
best performing high-technology growth sectors
• R&D investment: 17,500 million Euro in 2000 (up from 4,300 million Euro in 1985)
• Trade surplus: 25,200 million Euro in 2000 (up from 5,100 million Euro in 1985).
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
Pharmaceutical R&D expenditure in Europe, USA and Japan
(Euro Million), 1990-2001
0
5
10
15
20
25
30
1990 1995 2000 2001
Europe
USA
Japan8.000
5.342
2.810
10.958
9.078
5.221
17.495
21.631
7.495
18.800
26.384
N.A.
(Source: EFPIA)
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
Location of R&D spending by EU pharma companies (%)
0
10
20
30
40
50
60
70
80
1990 1995 1999
European Union
United States
Rest of the world
73
26
1
69
26
5
59
34
7
(Source: EFPIA)
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
Origin of the top 10 medicines by worldwide sales
0 2 4 6 8 10
2000
1992
Europe
Europe
USA
USA
(Source: EFPIA)
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
The Innovation Cycle in Drug Discovery
1. Europe is STRONGin Life Sciences.
2. Europe is WEAKin the market.
3. There is insufficient investment flowing to the critical development stages between basic research
and the market.
New R&D investment
TechnologicalDevelopment
Product and ProcessDevelopment
MarketResearch
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
“Towards a European research area” - COM 2000(6)
Proposes better framework conditions to foster integration of research activities and coordination of research and innovation policies
THE POLITICAL DRIVE
Lisbon Summit - March 2000
Sets a strategic goal for Europe to become the most competitive and dynamic knowledge-based economy in the world
Barcelona Summit - March 2002
Calls for adoption of the 6th Framework Programme by June 2002, agrees that research spending in the EU should approach 3% GDP
by 2010, with two thirds coming from business, stresses the importance of frontier technologies for future growth and welcomes the Commission's strategic vision for biotechnology and life sciences
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
Linking the ability to discover to the ability to produce
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
Improving the diagnostic and therapeutic arsenal for health care
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
Cell Factory Key ActionCell Factory Key ActionA strategy for Health and Drug DiscoveryA strategy for Health and Drug Discovery
New safermedicines faster
Preparing the regulatory
frame for new medicines
Promoting dialogue between industry,
academics, clinicians, patients, regulators
Financing R&D projects101 projects 1999-Sept.2001
200 Million Euros EU contribution
Science, research and development European Commission
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
Drug discovery R&D projects
Cell Factory (Framework Programme 5: 1998-2002)
Number EC contribution of projects (in Million Euro)
Drug discovery 56 110.01
New therapeutic strategies 39 79.84
In vitro tests 6 10.49
TOTAL 101 200.34
Science, research and development European Commission
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
Life Sciences, Genomics and Biotechnology for Health (FP6)L
ife
Sci
ence
s, G
enom
ics
&bi
otec
hnol
ogy
for
heal
th
• Advanced Genomics and its applications for health (1100 M€)
– Fundamental knowledge and basic tools for functional genomics in all organisms (Structural genomics; proteomics; comparative genomics; bioinformatics; Multidisciplinary genomics approaches to basic biological processes)
– Application of knowledge and technologies in the field of genomics and biotechnology for health (Technology platforms; support to start-up companies)
• Advanced Genomics and its applications for health (1100 M€)
– Fundamental knowledge and basic tools for functional genomics in all organisms (Structural genomics; proteomics; comparative genomics; bioinformatics; Multidisciplinary genomics approaches to basic biological processes)
– Application of knowledge and technologies in the field of genomics and biotechnology for health (Technology platforms; support to start-up companies)
•Combating major diseases (1155 M€)
– Application-oriented approach to medical genomics knowledge (Cardiovascular disease, diabetes and rare diseases ; resistance to antibiotics ; Studying the brain and combating diseases of the nervous
system ; Studying human development and the ageing process) – Broader biomedical approach (cancer, poverty-related infectious diseases)
•Combating major diseases (1155 M€)
– Application-oriented approach to medical genomics knowledge (Cardiovascular disease, diabetes and rare diseases ; resistance to antibiotics ; Studying the brain and combating diseases of the nervous
system ; Studying human development and the ageing process) – Broader biomedical approach (cancer, poverty-related infectious diseases)
Science, research and development European Commission
Application of knowledge and technologies in the field of genomics and biotechnology for health
(1.1.1.b)
“The strategic objective of this line is to foster the competitiveness of Europe’s biotechnology industry by exploiting the wealth of biological data produced by genomics and advances in biotechnology”.
Council Decision of 30/09/2002
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
Application of knowledge and technologies in the field of genomics and biotechnology for health
111ib
Rational and accelerated development of new, safer and more effective drugs including pharmacogenomics approaches
Development of new diagnostics
Development of new in-vitro tests to replace animal experimentation
Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, for example those on neurological and neuromuscular disorders) and immunotherapies
Innovative research in post-genomics, which has high potentialfor application
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
The topics in the Workprogramme must be contemplated against the background of:
Translational approach
Enhance the European biotechnology industry
Innovation in the health sector of the biotechnology industry, especially SMEs
Stimulation of entrepreneurship and opportunities through venture capital and the EIB
Identification of regulatory bottlenecks in the new applications for genomics
Anticipation of ethical implications
Council Decision of 30/09/2002
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European CommissionNetworks of Excellence:
Objectives
To structure the EU research potential
by integrating research capacities• Joint research activities• Integrating activities• Spreading of excellence• Common management
Management Group
Eu
rop
ean
Com
mis
sion
Research team leader
Management Group
• Joint research activities
• Integrating activities
• Spreading of excellence (training)
• Common management
To structure the EU research potential by integrating existing research capacities
Governing Council Funding Bodies Representatives
Partner Organisation Representative
Scientific Council
Science, research and development European Commission
Integrated projects: Objectives
Training
Ethical aspects, science-society dialogueEthical aspects, science-society dialogue
Technology transfer, exploitationTechnology transfer, exploitation
strong managementstructure
ImplementationPlan
RTD 4
RTD 1
RTD 2
RTD 3
RTD 5
Demonstration
ManagementManagement
addressing major societal needs increasing EU competitiveness
predefined S/Tresults and
clear deliverables
To integrate the critical mass of activities/resources needed for :
Science, research and development European Commission
Overview of the Selection : 2nd CallOverview of the Selection : 2nd Call
Instrument Response Priority Main Priority Reserve No-Go &(Nr of prop.) List (1) List Ineligible
IP 48 11 8 3 37NoE 14 7 6 1 7STREP 28 14 14 - 14SSA 14 5 5 - 9CA 2 0 0 -
Total 109(*) 37 33 4 69
(*) 3 ineligible(1) Proposals having passed the thresholds
Science, research and development European Commission
Evaluation criteriaEvaluation criteria
Relevance
Potential impact
Excellence of the participants
Degree of integration and the JPA
Organisation and management
S&T excellence
Quality of the consortium
Quality of the management
Mobilisation of the resources
Network of Excellence
X
X
X
X
X
Integrated projects
X
X
X
X
X
X
Science, research and development European Commission
Integrated projects Integrated projects Reasons for failing evaluation criteriaReasons for failing evaluation criteria
1. S&T excellence
2. Overall
3. Relevance
4. Potential impact
Science, research and development European Commission
Evaluation criteria : S&T Excellence (IP)Evaluation criteria : S&T Excellence (IP)
COMMENT• “…clear ambition…clear
and relevant objectives.”• “…S&T very good …
objectives clearly defined…”
• “….limited applications…objectives too narrow…over ambitious”
• “…unfocussed work plan…”
MARK
• 4 - 5
• 2.5 - 3.5
Science, research and development European Commission
Evaluation criteria : Relevance (IP)Evaluation criteria : Relevance (IP)
COMMENT• “…excellent relevance• “….exactly matches
the objectives …”• “…. addresses the
objectives• “…partially addresses
scope of the Call…”• “…does not fit the
objectives of the Call…”
MARK
• 4 - 5
• 3 – 3.5
• 2.5
• 0 - 1
Science, research and development European Commission
Evaluation criteria : Overall (IP)Evaluation criteria : Overall (IP)
COMMENT• “…(some issues)
should have been dealt with in greater detail…”
• “…some partners not involved…
• over ambitious goals…
• management insufficient”
MARK
JUST BELOW THE THRESHOLD
Science, research and development European Commission
Networks of ExcellenceNetworks of Excellence Reasons for failing evaluation criteria Reasons for failing evaluation criteria
1. Degree of Integration, JPA
2. Potential impact
3. Overall
Science, research and development European Commission
Networks of ExcellenceNetworks of Excellence Evaluation criteria : Degree of Integration Evaluation criteria : Degree of Integration
& JPA& JPA
COMMENT• “…missing
information…partners (industrial)...”
• “…lower than expected integration…”
• “…no lasting integration…”
MARK• 3.5
• 2
Science, research and development European Commission
STREPsSTREPs Reasons for failing evaluation criteria Reasons for failing evaluation criteria
1. S&T excellence
2. Relevance
Science, research and development European Commission
Evaluation criteria : S&T Excellence Evaluation criteria : S&T Excellence (STREP)(STREP)
COMMENT• “…objectives clearly
stated...”• “….[adds] no real value
to the state of the art”• “ …fails to develop
(x,y,z…)• “…unfocussed work
plan…”
MARK
• 4 - 5
• 3
Science, research and development European Commission
Evaluation criteria : Overall remarksEvaluation criteria : Overall remarks
• Incomplete/Absent Work Packages, absent elements in the research & development programme,
– Necessary partners absent : regulators, societal, industrial etc.– SMEs underrepresented/absent/de facto subcontractors
• Financial plans non-transparent– budget overinflated– distribution of funds inadequately justified
• Partial or no relevance to Work Programme• Project management inadequately described
– no clear management structure– fragmented / overlapping activities – no role definition for partner(s)
• Inappropriately qualified personnel
Science, research and development European Commission
Number of proposals: 8 IP6 NoE14 STREP5 SSA33 Total (32 topics)
All topics where proposals passed the threshold are covered
Budget: 161,31 Mio Euro (Indicative budget 165 Mio Euro)
SME participation: 23,2% (budget) and 16,9% (Nr of participants)
Budget requested by SME (in %): 27.3 IP22.6 NoE14.5 STREP
Industrial participation: 14%
Ratio NI / TI (budget): 79.8 / 20.2
Overview of the SelectionOverview of the Selection
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
SMEs are defined as enterprises which:
have fewer than 250 employees, and have either an annual turnover not exceeding € 40
million, or an annual balance-sheet total not exceeding in € 27
million
(Ref. 96/280/EC: Commission Recommendation of 3 April 1996 concerning the definition of small and medium-sized enterprises (Text with EEA relevance), Official Journal L 107 , 30/04/1996 P. 0004 - 0009)
SMEs
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
SMEs
Academia + others
83,7%
LARGE IND
1,7% SME 14,6 %
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Warsaw, POLAND 22.6.2004
EU contribution to SME contractors in IPs and STREPs was 14.6 % (22.7 M€). Adding large industries (1.7 %) will increase EU contribution to 16.3 % (25.3 M€).
Science, research and development European Commission
SMEs
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
63 SME contractors out of 335 partners (18.8 %).
SME19%
Academia + others
77%
IND4%
Science, research and development European Commission
SMEs
A large majority (95%) of the SME contractors is industrial SMEs.
SME-other5%
IND-SME95%
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Science, research and development European Commission
SME Dimension of the Selection
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
0
5
10
15
20
25
30
Response Priority List Main Priority List2nd Call
Main Priority List1st Call
IP
NoE
STREP
Average
Science, research and development European Commission
IP New approaches for accelerated development of new, safe and more effective medicines
IP Pharmacogenomics for individualised medicinesIP Exploring the potential of stem cells and/or primary cells,
for the understanding of monogenic rare diseases and the development of new drugs for their treatment
STREP Standardised assays for determining immunogenicity of biopharmaceuticals STREP 'Microdosing' studies to gain enhanced absorption, distribution, metabolism, excretion (ADME) - parameters for biopharmaceuticals (especially orientated towards involvement of SMEs)STREP Targeted delivery of protein-based drugs (especially orientated towards
involvement of SMEs) SSA Interdisciplinary educational approaches on the biological responses to
new biopharmaceuticals ( e.g. training events, workshops)
IP New approaches for accelerated development of new, safe and more effective medicines
IP Pharmacogenomics for individualised medicinesIP Exploring the potential of stem cells and/or primary cells,
for the understanding of monogenic rare diseases and the development of new drugs for their treatment
STREP Standardised assays for determining immunogenicity of biopharmaceuticals STREP 'Microdosing' studies to gain enhanced absorption, distribution, metabolism, excretion (ADME) - parameters for biopharmaceuticals (especially orientated towards involvement of SMEs)STREP Targeted delivery of protein-based drugs (especially orientated towards
involvement of SMEs) SSA Interdisciplinary educational approaches on the biological responses to
new biopharmaceuticals ( e.g. training events, workshops)
Rational and accelerated development of new, safer and more effective drugs (topics in the third call 2004)
Lif
e S
cien
ces,
Gen
omic
s &
biot
echn
olog
y fo
r he
alth
Science, research and development European Commission
IP Screening techniques and strategies in the early diagnosis of solid tumors
STREP Highly sensitive tests for the assessment of haematological malignancies (especially orientated towards involvement of SMEs)
STREP Genetic and molecular diagnostic markers of alcoholic liver diseases (especially orientated towards involvement of SMEs)
STREP New diagnostic tools for human and animal prion associated diseases (especially orientated towards involvement of SMEs)
SSA Workshop on the monitoring of safety of human blood origin products
SSA Workshop on ethical issues raised by new diagnostic methods
SSA Workshop on trends and perspective in new diagnostics
IP Screening techniques and strategies in the early diagnosis of solid tumors
STREP Highly sensitive tests for the assessment of haematological malignancies (especially orientated towards involvement of SMEs)
STREP Genetic and molecular diagnostic markers of alcoholic liver diseases (especially orientated towards involvement of SMEs)
STREP New diagnostic tools for human and animal prion associated diseases (especially orientated towards involvement of SMEs)
SSA Workshop on the monitoring of safety of human blood origin products
SSA Workshop on ethical issues raised by new diagnostic methods
SSA Workshop on trends and perspective in new diagnostics
Development of new diagnostics(topics in the third call 2004)
Lif
e S
cien
ces,
Gen
omic
s &
biot
echn
olog
y fo
r he
alth
Science, research and development European Commission
IP Cell systems as a means to enhance toxicity testing
STREP Optimization and pre-validation of in-vitro models for the study of drug absorption, modification and detoxification in the liver and in the intestinal
epithelium (especially orientated towards involvement of SMEs)
SSA Socio-economic impact on the "Three Rs" of the portfolio of the 5 research contracts in the "Cell Factory" 5th Framework Programme,
area 3.1.4
SSA Workshop: how to integrate and make optimal use of animal data, non-animal data and predictions from computer-based modelling in
assessing the risk of chemical compounds
SSA Mini-pigs as models for toxicity testing of new drugs and chemicals: impact assessment
IP Cell systems as a means to enhance toxicity testing
STREP Optimization and pre-validation of in-vitro models for the study of drug absorption, modification and detoxification in the liver and in the intestinal
epithelium (especially orientated towards involvement of SMEs)
SSA Socio-economic impact on the "Three Rs" of the portfolio of the 5 research contracts in the "Cell Factory" 5th Framework Programme,
area 3.1.4
SSA Workshop: how to integrate and make optimal use of animal data, non-animal data and predictions from computer-based modelling in
assessing the risk of chemical compounds
SSA Mini-pigs as models for toxicity testing of new drugs and chemicals: impact assessment
Development of new in vitro tests to replace animal experimentation(topics in the third call 2004)
Lif
e S
cien
ces,
Gen
omic
s &
biot
echn
olog
y fo
r he
alth
Science, research and development European Commission
IP Overcoming the limitations of stem cell therapy for solid tumours
IP Chemokines: A new therapeutic approach for chronic inflammation and autoimmune diseases
NoE Quality and safety standards for clinical gene transfer
STREP Development of new non-viral gene delivery technologies for ex vivo gene-based therapies (especially orientated towards involvement of
SMEs)STREP Human stem cells for spinal cord injury repairSTREP Exploring the potential of human umbilical cord blood stem cells for application other than allogeneic haematopoietic transplantationsSTREP Oncolytic virus vectors for cancer virotherapy
(especially orientated towards involvement of SMEs) SSA Workshop on use of stem cells as a tool for gene therapy
IP Overcoming the limitations of stem cell therapy for solid tumours
IP Chemokines: A new therapeutic approach for chronic inflammation and autoimmune diseases
NoE Quality and safety standards for clinical gene transfer
STREP Development of new non-viral gene delivery technologies for ex vivo gene-based therapies (especially orientated towards involvement of
SMEs)STREP Human stem cells for spinal cord injury repairSTREP Exploring the potential of human umbilical cord blood stem cells for application other than allogeneic haematopoietic transplantationsSTREP Oncolytic virus vectors for cancer virotherapy
(especially orientated towards involvement of SMEs) SSA Workshop on use of stem cells as a tool for gene therapy
Development and testing of new preventative and therapeutic tools such as somatic gene and cell therapies and immunotherapies
(topics in the third call 2004)
Lif
e S
cien
ces,
Gen
omic
s &
biot
echn
olog
y fo
r he
alth
Science, research and development European Commission
IP Post genomic approaches to understand the molecular basis of asthma aiming at a preventive or therapeutic control
IP Post genomic approaches for inflammatory rheumatic disease, leading to the development of improved therapy
IP Post-genomic approaches to a human pandemic influenza vaccine
STREP Post genomic approaches for tackling complex multifactorial diseases (except Cancer) (especially orientated towards involvement of SMEs)
IP Post genomic approaches to understand the molecular basis of asthma aiming at a preventive or therapeutic control
IP Post genomic approaches for inflammatory rheumatic disease, leading to the development of improved therapy
IP Post-genomic approaches to a human pandemic influenza vaccine
STREP Post genomic approaches for tackling complex multifactorial diseases (except Cancer) (especially orientated towards involvement of SMEs)
Innovative research in post genomics(topics in the third call 2004)
Lif
e S
cien
ces,
Gen
omic
s &
biot
echn
olog
y fo
r he
alth
Science, research and development European Commission
Technology Platform
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Technological platforms have the primary objective of defining a coherent and unified approach to tackling a major economic, technological or societal challenge of vital importance for Europe’s future competitiveness and economic growth.
Science, research and development European Commission
Technology Platform
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Key features:
• A shared vision and the commitment to put it into reality
• Strategic research agenda• Very large scale, highly
ambitious and complex• Industry-driven• Very substantial public and
private investment• Very high economic potential
Science, research and development European Commission
ETP: Innovative Medicines for Europe
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Objective:
To enhance and accelerate the development process of medicines to ensure a rapid translation of scientific breakthroughs to approved medicines. In particular through reinforced public-private partnerships early access to new, more targeted medicines shall be provided to the European population, while strengthening the European Science base and fostering economic growth in the pharma/biotech industry
Science, research and development European Commission
ETP: Innovative Medicines for Europe
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Stakeholders:
Industry (Pharmaceutical & Biopharmaceutical)
Public authorities (e.g. policymakers, regulatory agencies)
Academic community (Universities, Research centres, Ethical experts)
Financial community (e.g. venture capital, EIB, EIF)
Users, consumers and civil society (e.g. Hospitals, Clinicians, Patients associations)
Science, research and development European Commission
ETP: Innovative Medicines for Europe
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Expected benefits:
Increased effectiveness of public and private R&D investment
Fostering of innovation and competitiveness
More efficacious medicines and Reduced treatment periods for
patients
Less medicines withdrawals from market
Shorter drug development times
Overall reduced healthcare cost
Improvement of public perception of pharmaceutical industry
Increase Europe’s attractiveness for researchers and industrial
investment
Science, research and development European Commission
ETP: Innovative Medicines for Europe
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Implementation
Short term (FP6)
Definition of strategic research agenda Mobilisation of public and private resources Establishment of communication/dialogue process
and supporting structure/secretariat Develop education/training opportunities
Science, research and development European Commission
ETP: Innovative Medicines for Europe
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Strategic research agenda
• Is a key deliverable• Setting out R&D priorities for medium/long term• Should address obstacles for future market
penetration
Science, research and development European Commission
ETP: Innovative Medicines for Europe
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Implementation :
• Medium and long term (FP7):
• Through existing instruments (IP, NoE, CA, SSA)
• Via Joint European Technology Initiatives (as defined in Art. 171 of EU treaty)
Science, research and development European Commission
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Joint European Technology Initiatives
Criteria:• Highly innovative Science and Technology• Multiple industrial users• Research agenda building upon existing
programmes, seeking for integration of efforts• Significant economic impact• Feasible only at European level• Key stakeholders with full commitment• Technical/operational framework defined
ETP: Innovative Medicines for Europe
Science, research and development European Commission
Evaluators in FP6
Science, research and development European Commission
Evaluators in FP6
Science, research and development European Commission
Evaluators in FP6
Science, research and development European Commission
Evaluators in FP6
Science, research and development European Commission
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Total
10%6%
84%
EU 15
10 New MS
3 Cand.Ctries
Evaluators in FP6
Science, research and development European Commission
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Nr. of experts by country
349
874 951
65
1119
3873
3309
846
14111304
85
543
4664
1198887 1004
1462
554335 204
254 128 159
631
3384
84204132
4187
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
BG RO TR CR PL EE LV LT HU CZ SK SI CY MT IRL I UK F E PT B NL L DK D S FI A EL
Evaluators in FP6
Science, research and development European Commission
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
Evaluators in FP6
% of total experts by country
BG1%
RO3%
TR3%
CR0%
PL3%
F11%
E10%
PT2%
B4%
NL4%
L0%
DK2%
D14%
S4%
FI3%
A3%
EL4%
HU2% CZ
1%SK1%
SI1% CY
0% MT0%IRL2%
UK10%
LV0%
LT1%
EE0%
I12%
Science, research and development European Commission
Success will depend on mobilisation of all actors
Industrial
Platforms
Academia
Private Sector
Civil Society
European
Investment Bank
RESEARCH DEVELOPMENT REGULATIONDELIVERABLES
FOR SOCIETY
ParliamentCommissionMember States
Ethical Bodies
SMEs
Clinicians
LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH